Martin J Blaser:正确认识粪菌移植带来的风险
  • 肠道微生态的失衡可以导致多种疾病,对于艰难梭菌感染来说FMT具有很好的疗效;
  • 当前,数百项旨在确定FMT在各种传染、代谢、免疫、神经性疾病和癌症中疗效的临床试验正在开展;
  • 两名患者的事例提示FMT可能带有在事后才能确定的风险,改进供体筛选肯定会降低已知风险;
  • 但FMT本身非常复杂,包括细菌、真菌、病毒等各种组分,或许很难确定具体的风险源;
  • 所以要重视研发有针对性的益生菌组合或者益生元,以及考虑噬菌体治疗的可行性等。
主编推荐语
高春辉
针对于粪菌移植(FMT)在临床上可能带来的风险,Martin J Blaser在NEJM杂志发表了评论文章,介绍了FMT在美国的发展情况,提示重视风险的同时也不能裹足不前,一方面开展更深入的供体筛查,另一方面寻找FMT的改进和替代疗法。NEJM同期刊发的另两篇相关文章的解读见此(查看文章)(查看文章
关键字
延伸阅读本研究的原文信息和链接出处,以及相关解读和评论文章。欢迎读者朋友们推荐!

Fecal Microbiota Transplantation for Dysbiosis — Predictable Risks

粪菌移植治疗肠道生态失衡:可预测的风险

10.1056/NEJMe1913807

2019-10-30, Editorial Material

Abstract & Authors:展开

Abstract:收起
This article has no abstract; the first 100 words appear below. The term “dysbiosis” usually refers to a change in the human microbiome from a healthy pattern toward a pattern associated with disease. Although the term is increasingly being used, the definition, not surprisingly, is vague. Yet dysbiosis has become an area of great interest in medical science.1-3 Important questions are whether we can recognize dysbiosis in patients with particular medical conditions and whether reversing it, if possible, will lead to improved health. We are at the early stages of understanding these concepts. Dysbiosis occurs most evidently in patients with Clostridioides difficile infection. In such patients, it is clear that after . . .

First Authors:
Martin J Blaser

Correspondence Authors:
Martin J Blaser

All Authors:
Martin J Blaser

图片
New England Journal of Medicine期刊

Donor Screening for Fecal Microbiota Transplantation

2019-10-30

评论